Pathways for all identified QTL | |||
---|---|---|---|
Pathway | P-value | Ratio: | Genes in pathway that were identified in current study |
1D-myo-inositol Hexakisphosphate Biosynthesis II (Mammalian) | 1.93E-03 | 4/19 | INPP5E,IPMK,SEC16A,PMPCA |
AMPK Signaling | 2.15E-03 | 13/178 | CHRNA5,MTOR,STRADA,AK8,INSR,CHRNA3,PPM1J,CHRNB4,PIK3R2,ADRA2A,TSC1,FOXO1,ADRA1A |
Angiopoietin Signaling | 1.22E-03 | 6/66 | NRAS,PIK3R2,BIRC5,CASP9,IKBKAP,FOXO1 |
Calcium Signaling | 1.51E-02 | 11/178 | CALR,CHRNA5,MYL4,CHRNB4,CAMK4,CHRNA3,CAMK1G,MEF2D,TPM1,RAP1A,MEF2A |
Cardiac Hypertrophy Signaling | 5.80E-03 | 14/223 | MTOR,MYL4,CAMK4,RHOC,IGF1R,NRAS,PIK3R2,RHOT1,ADRA2A,MEF2D,MAP3K3,CACNA1D,MEF2A,ADRA1A |
D-myo-inositol (1,3,4)-trisphosphate Biosynthesis | 1.93E-03 | 4/19 | INPP5E,IPMK,SEC16A,PMPCA |
D-myo-inositol (1,4,5)-trisphosphate Degradation | 1.44E-02 | 3/18 | INPP5E,SEC16A,PMPCA |
Dopamine Degradation | 8.29E-03 | 4/28 | ALDH1A1,ALDH1A3,MAOB,ALDH4A1 |
ERK5 Signaling | 2.28E-03 | 7/63 | MAP2K5,NRAS,NTRK1,MEF2D,NGF,MAP3K3,MEF2A |
Ethanol Degradation IV | 4.02E-03 | 4/23 | ALDH1A1,TYRP1,ALDH1A3,ALDH4A1 |
Glioblastoma Multiforme Signaling | 1.03E-02 | 10/146 | WNT2B,IGF1R,NRAS,MTOR,PIK3R2,WNT5A,RHOC,RHOT1,TSC1, FOXO1 |
Glioma Signaling | 7.71E-03 | 8/98 | ABL1,TGFA,IGF1R,NRAS,MTOR,PIK3R2,CAMK4,CAMK1G |
Histamine Degradation | 1.22E-02 | 3/17 | ALDH1A1,ALDH1A3,ALDH4A1 |
Human Embryonic Stem Cell Pluripotency | 1.85E-03 | 11/134 | WNT2B,PIK3R2,WNT5A,SMAD3,SMAD6,NTRK1,TCF7L2,BMP2,NGF,FOXO1,NOG |
Non-Small Cell Lung Cancer Signaling | 1.13E-02 | 6/65 | ABL1,TGFA,NRAS,PIK3R2,CASP9,RXRA |
Nur77 Signaling in T Lymphocytes | 1.26E-03 | 7/57 | MAP2K5,SIN3B,CASP9,RXRA,CAMK4,MEF2D,MAP3K3 |
Putrescine Degradation III | 2.84E-03 | 4/21 | ALDH1A1,ALDH1A3,MAOB,ALDH4A1 |
Superpathway of D-myo-inositol (1,4,5)-trisphosphate Metabolism | 4.71E-03 | 4/24 | INPP5E,IPMK,SEC16A,PMPCA |
Thyroid Cancer Signaling | 9.69E-04 | 6/40 | NRAS,RET,RXRA,NTRK1,TCF7L2,NGF |
Tryptophan Degradation X (Mammalian, via Tryptamine) | 4.02E-03 | 4/23 | ALDH1A1,ALDH1A3,MAOB,ALDH4A1 |
Pathways identified for co-localized QTL | |||
Pathway | P-value | Ratio: | Genes in pathway that were identified in current study |
2-oxobutanoate Degradation I | 4.22E-02 | 1/5 | MCEE |
AMPK Signaling | 4.42E-03 | 6/178 | CHRNA5,PPM1J,CHRNB4,INSR,CHRNA3,ADRA1A |
Calcium Signaling | 1.55E-04 | 8/178 | CALR,CHRNA5,CHRNB4,CHRNA3,CAMK1G,TPM1,RAP1A,MEF2A |
Cardiac Hypertrophy Signaling | 4.35E-02 | 5/223 | IGF1R,NRAS,RHOC,MEF2A,ADRA1A |
CDK5 Signaling | 4.94E-02 | 3/105 | NRAS,PPM1J,NGF |
Cholecystokinin/Gastrin-mediated Signaling | 4.95E-02 | 3/245 | NRAS,RHOC,MEF2A |
CTLA4 Signaling in Cytotoxic T Lymphocytes | 4.01E-02 | 3/88 | PPM1J,PTPN22,AP1M1 |
ERK5 Signaling | 1.69E-02 | 3/63 | NRAS,NGF,MEF2A |
Germ Cell-Sertoli Cell Junction Signaling | 4.93E-02 | 4/160 | NRAS,TJP1,RHOC,RAB8B |
Glioblastoma Multiforme Signaling | 3.73E-02 | 4/146 | WNT2B,IGF1R,NRAS,RHOC |
Glioma Signaling | 1.01E-02 | 4/98 | TGFA,IGF1R,NRAS,CAMK1G |
Integrin Signaling | 3.33E-02 | 5/207 | NRAS,TSPAN2,RHOC,TLN2,RAP1A |
Methylmalonyl Pathway | 3.39E-02 | 1/4 | MCEE |
mTOR Signaling | 2.28E-02 | 5/187 | NRAS,PPM1J,INSR,RHOC,RPS15 |
NF-κB Signaling | 1.65E-02 | 5/172 | TGFA,IGF1R,NRAS,INSR,NGF |
PTEN Signaling | 1.89E-02 | 4/118 | IGF1R,NRAS,INSR,MAGI3 |
Renal Cell Carcinoma Signaling | 2.32E-02 | 3/71 | TGFA,NRAS,RAP1A |
STAT3 Pathway | 2.49E-02 | 3/73 | IGF1R,NRAS,INSR |
TCA Cycle II (Eukaryotic) | 1.65E-02 | 2/23 | IDH3A,ACO1 |
Thyroid Cancer Signaling | 4.62E-02 | 2/40 | NRAS,NGF |